PALI compared with BBNX: revenue, margins and what each company keeps, and the suppliers and customers both name

PALIPalisade Bio, Inc.

Mkt capRevenueRevenue

BBNXBeta Bionics, Inc.

Mkt capRevenueRevenue

Compare

PALIPalisade Bio, Inc.

BBNXBeta Bionics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

PALI: latest quarter is a loss; flow not drawable. BBNX: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only PALI 2

—Giiant Pharmaunlistedsupplier

—Newsoaraunlistedcustomer

Shared 0

No disclosed counterparties: BBNX.

Only BBNX 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

PALI, solidBBNX, dashed

PALIPalisade Bio, Inc.

1.17▼−1.97%· post 1.16

Mkt cap$202.2MRevenue$500,000Q2 FY26Revenue—

BBNXBeta Bionics, Inc.

16.78▼−4.57%· post 16.78

ClosedOct 30 '26

Mkt cap$779.6MRevenue$36MQ3 FY26Revenue$100MFY25

Compare

ClosedOct 30 '26

PALIPalisade Bio, Inc.

BBNXBeta Bionics, Inc.

1.17▼−1.97%post 1.16

Price

16.78▼−4.57%post 16.78

$202.2M

Mkt cap

$779.6M

Q2 FY26$500,000

Revenue

$36MQ3 FY26

—

Revenue

$100MFY25

PALI1.17▼−1.97%vsBBNX16.78▼−4.57%ClosedOct 30 '26